Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Affiliation

Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E. 66th Street, Room 1033, New York, NY, 10065, USA. [Email]

Abstract

Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma; however, there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examined the efficacy and safety of modified docetaxel, cisplatin and 5 fluorouracil (mDCF) plus trastuzumab in a single-arm multicenter phase II trial.

Keywords

Docetaxel,Gastric cancer,HER2,Trastuzumab,